Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:30.727Z.
Calculation as of: 2026-10-06T16:57:30.727Z.
Quote observation: 2026-10-06T16:54:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9bf447c1d5373d17b51517f64cfe8ce44e33b4ae98b3907fdc05662a19d62e0e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Metagenomi, Inc. Common Stock
Market Cap
$40.09M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.61M
EV/EBITDA Ratio
10.54x
TTM Avg
9.64x
3Y Avg
45.33x
5Y Avg
52.62x
Market Cap
$41.92M
EV/EBITDA Ratio
N/A
TTM Avg
1378.16x
3Y Avg
1378.16x
5Y Avg
1378.16x
Market Cap
$37.93M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$43.51M
EV/EBITDA Ratio
23.65x
TTM Avg
28.58x
3Y Avg
33.75x
5Y Avg
33.75x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $40.09M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.22M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $39.84M | 20.41x | 31.88x | 41.18x | 41.18x |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | 10.54x | 9.64x | 45.33x | 52.62x |
| Precipio, Inc. (PRPO)vs › | $41.92M | N/A | 1378.16x | 1378.16x | 1378.16x |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.60M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.18M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $43.51M | 23.65x | 28.58x | 33.75x | 33.75x |
| BioStem Technologies, Inc. (BSEM)vs › | $43.65M | N/A | 7.89x | 10.87x | 10.87x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
